Tobacco Companies Reach Settlement With Texas for $15.3 Billion

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

TEXARKANA, Tex-The tobacco industry has reached a settlement with the State of Texas worth $15.3 billion, the largest such settlement to date. Previously, the companies settled with Mississippi for $3.4 billion and with Florida for $11.3 billion. The state’s private trial lawyers will receive 15% of the sum in fees, a total of more than $2.2 billion.

TEXARKANA, Tex—The tobacco industry has reached a settlement with the State of Texas worth $15.3 billion, the largest such settlement to date. Previously, the companies settled with Mississippi for $3.4 billion and with Florida for $11.3 billion. The state’s private trial lawyers will receive 15% of the sum in fees, a total of more than $2.2 billion.

The settlement is to reimburse the state for Medicaid money spent to treat people with smoking-related illnesses. The money is earmarked for state antismoking campaigns, but Texas lawmakers have said that only the Legislature has the authority to decide how to spend state funds.

Although the settlement perhaps helps clear the way for Congress to consider the proposed $368.5 billion agreement between the companies and more than 40 state attorneys general, another trial is looming in Minnesota, where attorney general Hubert Humphrey III has vowed to make the companies pay heavily.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content